Home > Insider Trading > Filing (0001104659-20-132451)

Filing Details

Accession Number:: 0001104659-20-132451
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-04 16:30:32
Reporting Period:: 2020-12-02

Accepted Time:: 2020-12-04 16:30:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	Yes
1346824	Ra Capital Management, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	Yes
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	Yes
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-02	18,879	$32.50	4,580,524	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-02	12,060	$32.23	4,568,464	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-03	10,582	$31.23	4,557,882	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-03	12,976	$29.11	4,544,906	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-03	139,308	$28.95	4,405,598	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-03	44,738	$28.75	4,360,860	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).
The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.
This transaction was executed in multiple trades at prices ranging from $31.90 to $32.67; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This transaction was executed in multiple trades at prices ranging from $29.23 to $32.23; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This transaction was executed in multiple trades at prices ranging from $29.00 to $29.51; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This transaction was executed in multiple trades at prices ranging from $28.75 to $29.00; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This transaction was executed in multiple trades at prices ranging from $28.74 to $28.75; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.